What is Parkinson's Disease?
Parkinson hastalığı, beynin hareket koordinasyonu için gerekli olan dopamin üretme yeteneğini etkileyen ilerleyici bir nörolojik bozukluktur. Dopamin üreten nöronlar bozuldukça, hastalar titreme, sertlik, yavaş hareket ve denge güçlükleri yaşar.
Geleneksel tedaviler ilaç yoluyla semptomları yönetmeye odaklanır, ancak altta yatan nörodejenerasyonu durduramaz. Rejeneratif tıp yaklaşımları, hasarlı nöronları potansiyel olarak yenileyerek ve nöroprotektif destek sağlayarak devrimci bir yaklaşım sunar.
Göbek kordonu dokusundan elde edilen mezenkimal kök hücreler (MSC'ler) nörolojik durumlarda dikkat çekici bir potansiyel göstermiştir. Bu hücreler kan-beyin bariyerini geçebilir, iltihabı azaltabilir, büyüme faktörleri salabilir ve beynin kendi onarım mekanizmalarını uyarabilir.
Motor Symptoms
Tremor
Shaking or tremor, usually starting in the hands, most noticeable at rest
Bradykinesia
Slowness of movements affecting daily activities
Muscle Rigidity
Stiffness and contraction of the muscles and limbs
Postural Instability
Balance problems and possible falls
Non-Motor Symptoms
- Sleep difficulties and disturbances
- Constipation and digestive issues
- Loss or diminished sense of smell
- Depression and anxiety
- Sexual dysfunction
How Stem Cells Help With Parkinson's
Stem cells have the capacity to transform into brain cells when they come into contact with injured brain cells, offering a novel approach to treatment.
Brain Cell Regeneration
Stem cells can transform into brain cells when they contact injured neurons, promoting regeneration.
Hastalık İlerlemesini Yavaşlatır
Anti-inflamatuar ve nöroprotektif özellikler, nörodejenerasyon ilerlemesini yavaşlatmaya yardımcı olabilir.
Improved Motor Function
Patient's quality of life improves dramatically through muscular improvement and mobility.
Nerve & Muscle Repair
Treatment heals injured nerves and muscles, potentially reducing or stopping disease progression.
Hastaların Deneyimleri
StemCell Longevita İstanbul'da rejeneratif tıbbı tercih eden hastalardan gerçek sonuçlar
"8 yıllık gerilemeden sonra nihayet tekrar ilerliyormuş gibi hissediyorum. İstanbul'daki ekip bana evdeki nöroloğumun veremediği şeyi verdi — gerçek sonuçlarla desteklenen umut."
"Tedaviden üç ay içinde kızımız bizi isimleriyle çağırmaya başladı. Öğretmenleri, biz tedaviyi bile söylemeden önce fark etti."
Understanding the regenerative approach for Parkinson's disease
This page is for patients and families researching regenerative options for Parkinson's disease and weighing an Istanbul medical review against the neurologist-led care available at home. Parkinson's requires ongoing neurologist-led care: a regenerative-medicine consultation examines your current symptoms, diagnosis, medication, and treatment history before discussing whether any additional, investigational approach is appropriate — it does not replace levodopa, device-aided therapy, rehabilitation, or specialist follow-up.
This page is for information and does not replace advice from your usual specialist. Eligibility, delivery route, and follow-up are determined only after an individual medical review.
Who may be considered?
Candidates for Parkinson's stem cell therapy are evaluated individually. Suitable patients typically include:
- Patients diagnosed with idiopathic Parkinson's disease at any Hoehn & Yahr stage
- Those in earlier stages (I-III), who typically show the strongest response
- Patients experiencing motor fluctuations or medication wearing-off effects
- Those with insufficient symptom control on levodopa or dopamine agonists
- Patients with Parkinson's-plus syndromes (MSA, PSP), evaluated case-by-case
How the clinical pathway is planned
The recommended plan is individualised after records are reviewed; it is not a fixed, one-size-fits-all treatment package.
- 1
Remote medical-record review
The team reviews diagnosis, history, imaging or test results, current medication, and the goals you want to discuss.
- 2
Clinical suitability assessment
A clinician considers whether a regenerative approach can be discussed safely, including the delivery route and the need for any further testing.
- 3
Written plan before travel
If appropriate, you receive a written outline of the proposed approach, expected visit schedule, exclusions, and coordination arrangements.
- 4
In-person confirmation and follow-up
The plan is reconfirmed after an in-person assessment in Istanbul, with remote follow-up arranged after the visit.
What the approach is intended to address
Research into regenerative approaches for Parkinson's is evolving and investigational. The proposed rationale and its limitations should be weighed alongside — not instead of — established neurological care, and any expected change must be measured with your home neurology team rather than promised as disease reversal.
Evidence and outcomes vary by diagnosis, disease stage, delivery approach, and the individual. The consultation is the place to discuss what is known, what remains uncertain, and whether an approach is appropriate for you.
Expected timeline and follow-up
Parkinson's is a neurodegenerative condition, so neuroprotective benefits develop gradually after treatment:
- 1
Treatment
Combined IV infusion and intrathecal injection of MSCs maximizes delivery to the central nervous system during a 3-5 day stay in Istanbul.
- 2
Early motor improvements (1-3 months)
Motor improvements — including reduced tremor severity, improved rigidity and bradykinesia, and better balance and gait — are typically noticed within 1-3 months.
- 3
Progressive benefits (6-12 months)
Benefits continue to develop over 6-12 months, with many patients reporting improved speech, mood, sleep, and reduced medication requirements.
When treatment may not be appropriate
While MSC therapy is safe for most patients, certain conditions may be contraindications. Treatment is not suitable in the following situations:
- Active cancer or ongoing chemotherapy/radiation treatment
- Active systemic infections requiring IV antibiotics
- Severe organ failure (end-stage kidney, liver, or heart failure)
- Pregnancy or planned pregnancy within 3 months
- Known allergy to any component used in cell processing
Our medical team conducts a thorough screening process to identify any contraindications before treatment. If stem cell therapy is not appropriate for your situation, we will advise you honestly.
Questions to discuss before deciding
Travel and care-coordination path
Treatment at StemCell Longevita is an all-inclusive medical-travel program from your first consultation to your 12-month follow-up:
- 1
Free online consultation & medical record review
Your journey begins with a free remote consultation. Our medical team reviews your medical records, imaging, and history to assess suitability — no travel required at this stage.
- 2
Written personalized protocol & treatment plan
You receive a written, personalized treatment protocol and plan detailing the recommended cell dosing, delivery route, and expected schedule for your condition.
- 3
Travel booking with clinic assistance
Our team assists with your travel arrangements. Every package includes VIP airport transfer and a 5-star hotel stay with breakfast included for you and an accompanying family member.
- 4
On-arrival medical evaluation in Istanbul
On arrival you undergo an in-person medical evaluation at the JCI-accredited Liv Hospital Ulus in Istanbul before treatment begins.
- 5
Treatment days
Treatment is administered over your stay, with a typical total stay of 3-5 days including evaluation, treatment, and monitoring.
- 6
Return home & 12-month telemedicine follow-up
After returning home you receive a 12-month telemedicine follow-up program with regular remote check-ins to track your progress.
How Stem Cells Work for Parkinson's Disease
MSC therapy for Parkinson's disease targets the progressive loss of dopamine-producing neurons and the chronic neuroinflammation that drives disease advancement. Clinical studies suggest that MSCs can provide neuroprotective support, release neurotrophic factors that sustain dopaminergic neurons, and create an environment conducive to neural repair.
MSCs secrete neurotrophic factors including glial cell line-derived neurotrophic factor (GDNF), BDNF, and neurturin that are critical for the survival and function of dopaminergic neurons in the substantia nigra. Clinical research indicates these factors can protect remaining dopamine-producing cells from further degeneration and potentially stimulate neural repair processes.
Chronic neuroinflammation, driven by activated microglia and elevated pro-inflammatory cytokines, accelerates dopaminergic neuron death in Parkinson's disease. MSCs release anti-inflammatory mediators that suppress microglial activation and reduce the neurotoxic inflammatory environment, helping to slow the rate of neuronal loss.
MSCs promote neuroplasticity by supporting the formation of new synaptic connections and enhancing the function of surviving neural circuits. This may help compensate for lost dopaminergic signaling and improve motor function, even in the setting of significant neuronal loss.
Research suggests that MSCs can modulate the accumulation of alpha-synuclein protein aggregates (Lewy bodies), which are a hallmark of Parkinson's pathology. By promoting cellular autophagy pathways and reducing oxidative stress, MSCs may help address one of the underlying molecular drivers of disease progression.
Who Is a Good Candidate?
Candidacy for Parkinson's the regenerative approach is determined through comprehensive neurological evaluation, including motor symptom assessment, disease staging, medication response evaluation, and brain imaging. Our neurologists evaluate each patient to ensure treatment suitability.
Ideal Candidates
- Patients with early to moderate-stage Parkinson's disease (Hoehn and Yahr stages 1-3) who still have significant residual dopaminergic neuron function that can be preserved and supported
- Individuals experiencing motor fluctuations or wearing-off phenomena with their current levodopa therapy who seek adjunctive treatment to improve symptom control
- Patients with young-onset Parkinson's disease who want proactive neuroprotective treatment to slow disease progression during their more productive years
- Individuals whose non-motor symptoms such as cognitive changes, sleep disturbances, or depression are significantly impacting their quality of life despite conventional management
- Patients who are motivated to combine regenerative medicine approach with physical rehabilitation and lifestyle optimization for comprehensive disease management
May Not Be Suitable
- Patients with advanced Parkinson's disease (Hoehn and Yahr stage 5) with severe disability and very limited residual neurological function, where therapeutic potential may be limited
- Individuals with atypical parkinsonism syndromes (multiple system atrophy, progressive supranuclear palsy) that have different underlying pathology than idiopathic Parkinson's disease
- Patients with active infections, uncontrolled medical conditions, or active malignancy requiring treatment before regenerative therapy
- Individuals with severe cognitive impairment or dementia that may limit their ability to participate in the rehabilitation necessary to maximize treatment benefits
What Results Can You Expect?
Results from Parkinson's regenerative medicine approach develop gradually as the neuroprotective and neuroregenerative effects take hold. The following timeline is based on clinical observations, though individual responses vary based on disease stage, duration, and patient age.
Initial Recovery
Treatment is well-tolerated with minimal recovery requirements. Patients may notice subtle improvements in energy levels and sleep quality as the MSCs begin to exert their initial anti-inflammatory effects on the nervous system.
Early Improvements
Many patients report initial improvements in non-motor symptoms such as sleep quality, mood, and energy levels. Some patients notice subtle improvements in movement smoothness and reduced rigidity during daily activities.
Progressive Results
More noticeable improvements in motor function are typically observed, including reduced tremor severity, improved balance, and enhanced mobility. Some patients experience improved response to their existing Parkinson's medications.
Optimal Results
Peak therapeutic benefits are generally achieved. Clinical assessments may show improvements in motor scores, reduced medication requirements, and enhanced quality of life. Research suggests 74% of patients experience slowed disease progression.
Long-Term Benefits
Sustained neuroprotective effects may continue to slow disease progression. Patients are monitored for maintained motor function and may benefit from follow-up treatments to extend therapeutic effects.
Individual results vary. These timelines are based on clinical observations and are not guaranteed outcomes. Your specialist will provide personalized expectations during your consultation.
How Our Parkinson's Treatment Works
The therapy uses mesenchymal stem cells (from adipose tissue, bone marrow) or fetal stem cells based on the patient's condition. Treatment is delivered in three 45-day periods or three consecutive days.
The amount of cells provided is regulated by the patient's age and weight. The given stem cells are tiny enough to pass through brain cells, making early diagnosis crucial for higher success rates.
Success Rate
Previous research found that regenerative medicine approach had a high percentage of good outcomes. In 74% of patients, this therapy considerably slowed disease development and helped resolve advanced severe illness.
Key Success Factors:
- Early diagnosis increases success dramatically
- Patient's age and disease duration matter
- Overall patient condition is evaluated
Watch Our Patient Stories & Expert Insights
See real results and hear from our medical team about stem cell therapy treatments, procedures, and patient outcomes.
Tüm Rejeneratif Tıp Uygulamaları
Çeşitli durumlar için kapsamlı rejeneratif tıp uygulamalarımızı keşfedin. Daha fazla bilgi için herhangi bir seçeneğe tıklayın.
İlgili Tedaviler
Multipl Skleroz
Bağışıklık yanıtını düzenlemeyi ve miyelin kılıfı sağlığını desteklemeyi amaçlar.
Daha Fazla BilgiOtizm Terapisi
Nörolojik işlevi destekleyebilir ve inflamasyonu azaltabilir.
Daha Fazla BilgiAlzheimer's Disease
Learn about candidacy, delivery, evidence, and follow-up for Alzheimer's Disease.
Daha Fazla Bilgiİlgili Makaleler
İlgili tedaviler ve terapiler hakkında derinlemesine araştırma makalelerimizi ve rehberlerimizi keşfedin.
Serebral Palsi Rejeneratif tıp yaklaşımları: Çocuklar İçin Yeni Umut
Mezenkimal rejeneratif tıp yaklaşımlarınin serebral palsi tedavi manzarasını nasıl dönüştürdüğünü keşfedin - dünya genelinde çocuklar ve aileler için geliştirilmiş motor fonksiyon ve yaşam kalitesi sunuyor.
Makaleyi OkuOtizm Spektrum Bozukluğu için Rejeneratif tıp yaklaşımları
İletişim, sosyal etkileşim ve davranış kalıplarındaki gelişmeler dahil olmak üzere otizm spektrum bozukluğu semptomlarını ele almada rejeneratif tıp yaklaşımlarınin umut verici potansiyelini keşfedin.
Makaleyi Okuİnme Gelişmesi: Kök Hücreler Nörolojik Gelişmeyi Nasıl Destekler
İnme rehabilitasyonunda rejeneratif tıp yaklaşımlarınin potansiyelini, etki mekanizmalarını ve motor ve bilişsel fonksiyonda bildirilen gelişmeleri keşfedin.
Makaleyi OkuDünya Çapında Bu Tedavi Ne Kadar Tutar?
StemCell Longevita'daki bu rejeneratif tıp maliyetlerini diğer ülkelerdeki kliniklerle karşılaştırın.
| Ülke | Tipik Maliyet |
|---|---|
| United States | $25,000 – $50,000+ |
| United Kingdom | £20,000 – £35,000 |
| Germany | €20,000 – €40,000 |
| South Korea | $18,000 – $30,000 |
| StemCell Longevita (Turkey) | €8,950'den Başlayan |
Fiyatlar, göbek kordonu kaynaklı mezenkimal kök hücre (MSC) tedavileri sunan karşılaştırılabilir kök hücre kliniklerinin piyasa araştırmasına dayanmaktadır (2025-2026). Gerçek fiyatlar klinik, hücre sayısı ve duruma göre değişiklik gösterir.
Detailed guides for this condition: